ADMA
Adma Biologics, Inc.
$9.08
-0.19 (-2.05%)
At close · Jul 10
Market Cap
$2.10B
Shares
231,772,715
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$510.17M
+19.6%
FY2025
Net Income
$146.93M
-25.7%
FY2025
Gross Margin
57.39%
+5.9pp
FY2025
Operating Margin
37.53%
+4.9pp
FY2025
Diluted EPS
$0.60
-25.9%
FY2025
Operating Cash Flow
$50.4M
-57.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $530M – $560M | $509.86M | $510.17M | $426.45M | $258.22M | $154.08M | $80.94M | $42.22M | $29.35M | $16.99M | $22.76M | $10.66M | $7.18M | $5.92M | $3.07M | $1.12M | $761.04K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$9759 | -$1.6M | |
| — | $197.45M | $217.41M | $206.9M | $169.27M | $118.82M | $79.77M | $61.29M | $39.5M | $42.19M | $29.16M | $1.61M | $4.31M | $3.74M | $2.02M | $669.06K | $207.57K | |
| — | $312.42M | $292.77M | $219.55M | $88.94M | $35.27M | $1.17M | -$19.07M | — | -$25.21M | -$6.4M | $4.3M | $2.87M | $2.17M | $1.04M | $449.06K | $553.47K | |
| — | — | 57.39% | 51.48% | 34.44% | 22.89% | 1.45% | -45.17% | — | -148.42% | -28.14% | 40.34% | 39.93% | 36.74% | 34.04% | 40.16% | 72.73% | |
| — | $2.6M | $4.76M | $1.81M | $3.3M | $3.61M | $3.65M | $5.91M | $2.34M | $3.93M | $5.57M | $7.69M | $7.02M | $9.52M | $9.3M | $3.47M | $646.76K | |
| — | $37.15M | — | — | — | — | — | $35.05M | $25.91M | $22.5M | $18.75M | $8.49M | $6.75M | $4.82M | $4.37M | $3.14M | $1.43M | |
| — | $94.24M | $91.58M | $74.12M | $59.02M | $52.46M | $42.9M | $35.05M | — | — | — | — | — | — | — | — | — | |
| — | $174K | $144K | $388K | $724K | $715K | $715K | $715.35K | $844.94K | $844.94K | $1.23M | $0 | — | — | — | — | — | |
| — | $7.9M | $8M | $7.7M | $7.6M | $6.4M | $4.8M | $3.2M | $2.4M | $2.6M | $1.5M | $400K | $469.82K | $247.85K | $210.63K | $182.09K | $219.55K | |
| — | $97.58M | $101.32M | $80.57M | $67.31M | $74.63M | $59.55M | $45.84M | $70.77M | $77.27M | $62.07M | $27.99M | $22.69M | $21.93M | $18.11M | $9.03M | $5.18M | |
| — | $214.84M | $191.44M | $138.98M | $21.63M | -$39.37M | -$58.37M | -$64.91M | -$41.42M | -$60.29M | -$39.31M | -$17.33M | -$15.51M | -$16.02M | -$15.04M | -$7.91M | -$4.62M | |
| — | — | 37.53% | 32.59% | 8.38% | -25.55% | -72.12% | -153.75% | -141.14% | -354.95% | -172.71% | -162.56% | -216.14% | -270.79% | -490.37% | -707.36% | -607.45% | |
| — | $222.74M | $199.44M | $146.68M | $29.23M | -$32.97M | -$53.57M | -$61.71M | -$39.02M | -$57.69M | -$37.81M | -$16.93M | -$15.04M | -$15.77M | -$14.83M | -$7.73M | -$4.4M | |
| — | $7.24M | $7.11M | $13.93M | $25.03M | $19.28M | $13.06M | $11.99M | $8.99M | $5.52M | $3.29M | $2.24M | $1.84M | $1.29M | $618.23K | $30.68K | $1.6M | |
| — | — | $1.87M | $2.1M | $1.62M | $45K | $35K | $288.13K | $800.79K | — | — | — | — | — | — | — | — | |
| — | -$8.5M | -$8.79M | -$13.27M | -$49.87M | -$26.54M | -$13.27M | -$10.83M | -$6.85M | -$5.45M | -$4.45M | -$2.18M | -$2.46M | -$1.35M | -$484.82K | -$9759 | — | |
| — | $206.33M | $182.66M | $125.71M | -$28.24M | -$65.9M | — | — | — | — | — | -$19.52M | -$17.97M | -$17.36M | -$15.53M | -$7.92M | -$6.22M | |
| — | $40.98M | $35.73M | -$71.96M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$551.72K | $0 | -$617.62K | — | |
| — | $165.35M | $146.93M | $197.67M | -$28.24M | -$65.9M | -$71.65M | -$75.75M | -$48.28M | -$65.74M | -$43.76M | -$19.52M | -$17.97M | -$16.81M | -$15.53M | -$7.3M | -$5.9M | |
| — | — | 28.8% | 46.35% | -10.94% | -42.77% | -88.52% | -179.41% | -164.5% | -387.06% | -192.26% | -183.05% | -250.36% | -284.22% | -506.17% | -653% | -775.71% | |
| USD/shares | — | — | $0.62 | $0.85 | -$0.13 | -$0.33 | -$0.51 | -$0.88 | — | — | — | — | — | — | — | — | — |
| USD/shares | — | — | $0.60 | $0.81 | -$0.13 | -$0.33 | -$0.51 | -$0.88 | — | — | — | — | — | — | — | — | — |
| shares | — | — | 238.3M | 233.08M | 223.98M | 197.87M | 139.58M | 86.15M | 54.35M | 45.19M | 22.9M | 12.15M | 10.41M | 9.29M | 6.53M | 5.27M | 353.1K |
| shares | — | — | 244.9M | 243.34M | 223.98M | 197.87M | 139.58M | 86.15M | 54.35M | 45.19M | 22.9M | 12.15M | 10.41M | 9.29M | 6.53M | 5.27M | 353.1K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2025: $32.09M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
4.24×
Biotechnology median 8.05×
EV/EBIT
10.07×
Biotechnology median 25.73×
P/E (TTM)
13.35×
Biotechnology median 7.52×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|
| ADMA Bio Manufacturing Segment | $493,000,000 | $415,806,000 | $249,738,000 | $144,070,000 | $74,936,000 | $36,673,287 | — |
| Plasma Collection Centers Segment | $17,030,000 | $10,505,000 | $8,334,000 | $9,867,000 | $5,864,000 | $5,403,662 | — |
| Adma Biomanufacturing | — | — | — | — | — | — | $22,176,699 |
| Consolidated | — | — | — | — | — | — | $29,349,083 |
| Plasma Collection Center | — | — | — | — | — | — | $7,029,550 |
| Corporate | — | — | $143,000 | — | $143,000 | $142,834 | $142,834 |
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| United States | $503,924,000 | $410,005,000 | $244,738,000 | $146,284,000 | $70,626,000 | $36,552,244 |
| Non Us | $6,106,000 | $16,306,000 | $13,334,000 | $7,653,000 | $10,317,000 | $5,667,539 |
By Product & Service (USD)
| Component | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Product | $153,936,858 | $80,799,791 | $42,076,949 |
| License And Service | $142,834 | $142,834 | $142,834 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| ADMA Bio Manufacturing Segment | $47,525,000 | $879,000 | -$29,294,000 | -$46,904,634 | — |
| Plasma Collection Centers Segment | -$4,048,000 | -$17,908,000 | -$12,056,000 | -$4,410,890 | — |
| Corporate | -$21,845,000 | -$22,336,000 | -$17,024,000 | -$13,599,353 | -$10,726,346 |
| Adma Biomanufacturing | — | — | — | — | -$29,360,522 |
| Consolidated | — | — | — | — | -$41,424,327 |
| Plasma Collection Center | — | — | — | — | -$1,337,459 |
Operating Margin by Segment (%)
| Component | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| ADMA Bio Manufacturing Segment | 19% | 0.6% | -39.1% | -127.9% | — |
| Plasma Collection Centers Segment | -48.6% | -181.5% | -205.6% | -81.6% | — |
| Adma Biomanufacturing | — | — | — | — | -132.4% |
| Consolidated | — | — | — | — | -141.1% |
| Plasma Collection Center | — | — | — | — | -19% |
| Corporate | -15276.2% | — | -11904.9% | -9521.1% | -7509.7% |
Key facts
CIK
1368514
CUSIP
000899104
13F (30d)
12 filings
12 filers
Visit website
Investor relations